Study 41 of 46Semaglutide literatureLancet (London, England)Top journal2026
Semaglutide treatment fails but might prevent Alzheimer's disease.
Not reported in abstract.
Where it sits
this study against the rest of the semaglutide corpus13
Preclinical · this one
24
Observational
2
Open-label
2
Randomised
5
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Semaglutide corpus
DRarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.Pharmaceutical biology · 2026 · Not reported in abstract.reviewBHunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.International journal of qualitative studies on health and well-being · 2026 · n=11 · Not reported in abstract.HumanDDaily briefing: Narcolepsy drug could kick off an Ozempic-style moment for the brain.Nature · 2026—DDoctor who prescribed Ozempic and Wegovy to her partner has suspension extended.BMJ (Clinical research ed.) · 2026—AOnce-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial.The lancet. Diabetes & endocrinology · 2026HumanD"GLP-1 patches": High street wellness brand slammed for its "literally Ozempic" ads.BMJ (Clinical research ed.) · 2026—